Another Cholesterol Medication Goes Down (Or Does It)?. In the Pipeline:

"This is turning into Cardiovascular Week around the blog, I have to say, and not in a good way. The latest news is the failure of a drug candidate from Takeda, TAK-475 (lapaquistat). They were in the lead in the field of squalene synthase inhibitors for cholesterol lowering (many other companies have taken a crack at this target, and dropped out along the way)., and their compound once had hopes of being a pretty big deal."

href="http://pipeline.corante.com/archives/2008/04/04/another_cholesterol_medication_goes_down_or_does_it.php">Another Cholesterol Medication Goes Down (Or Does It)?. In the Pipeline: